This week's round-up of pharma licensing deals features alliances involving Tenaya Therapeutics, Sino Bio, Antengene, and A2A ...
Bimekizumab was superior to risankizumab at 16 weeks for improving PsA symptoms in a head-to-head clinical trial.
1 Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA 2 Department of Epidemiology, Harvard T H ...
In case you had any doubt, Elon Musk’s X has an algorithm that favors conservative content posted by political activists over liberal content or posts by traditional news media accounts, according to ...
A new study published in Nature has found that X's algorithm—the hidden system or "recipe" that governs which posts appear in your feed and in which order—shifts users' political opinions in a more ...
The X algorithm’s promotion of conservative content may shift the political opinions of those who switch to its “For You” tab after previously using a purely chronological feed, a study published ...
Hosted on MSN
Belgium's UCB in autoimmune drug deal with Antengene
Belgian drugmaker UCB has entered into an agreement to licence Antengene's experimental autoimmune disease therapy ATG-201 and associated technology, paying $60 million up front and over $1.1 billion ...
United Community Banks Inc. Annual stock financials by MarketWatch. View the latest UCB financial statements, income statements and financial ratios.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results